Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

BACKGROUND: The PRIMA phase 3 trial showed niraparib significantly prolongs median progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer (OC) responsive to first-line platinum-based chemotherapy, including those who had tumors with homologous recombination deficienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Barretina-Ginesta, Maria-Pilar, Monk, Bradley J., Han, Sileny, Pothuri, Bhavana, Auranen, Annika, Chase, Dana M., Lorusso, Domenica, Anderson, Charles, Abadie-Lacourtoisie, Sophie, Cloven, Noelle, Braicu, Elena I., Amit, Amnon, Redondo, Andrés, Shah, Ruchit, Kebede, Nehemiah, Hawkes, Carol, Gupta, Divya, Woodward, Tatia, O’Malley, David M., González-Martín, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511290/
https://www.ncbi.nlm.nih.gov/pubmed/36172173
http://dx.doi.org/10.1177/17588359221126149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511290/
https://www.ncbi.nlm.nih.gov/pubmed/36172173
http://dx.doi.org/10.1177/17588359221126149

Ejemplares similares